Visual acuity ≥ 5/200 at 3 years · surgery for retinal detachment associated with proliferative vitreoretinopathy
Silicone oil showed no clear difference in visual acuity ≥ 5/200 at 3 years compared with perfluropropane (C3F8) (low certainty).
1 finding from 1 review
Macular attachment at 18 months · surgery for retinal detachment associated with proliferative vitreoretinopathy
Silicone oil showed no clear difference in macular attachment at 3 years compared with perfluropropane (C3F8) (low certainty).
1 finding from 1 review
Lung function(FEV1 or FVC L/min or % predicted) · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to next exacerbation · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa
1 finding from 1 review
Quality of life · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sputum bacterial density (CFU/mL) · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 1 year · people with hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with hepatocellular carcinoma
1 finding from 1 review
Cancer‐related mortality at maximal · people with hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to progression of the tumour · people with hepatocellular carcinoma
1 finding from 1 review
Disease control rate · people with hepatocellular carcinoma
It is very uncertain whether radioembolisation changes disease control rate compared with sorafenib (very low certainty).
1 finding from 1 review
Non‐serious adverse events (hand‐foot skin reaction) · people with hepatocellular carcinoma
Radioembolisation may leads to lower non‐serious adverse events (hand‐foot skin reaction) compared with sorafenib (low certainty).
1 finding from 1 review
All‐cause mortality at 1 year · people with hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with hepatocellular carcinoma
1 finding from 1 review
Serious adverse events · people with hepatocellular carcinoma
It is very uncertain whether radioembolisation changes serious adverse events compared with chemoembolisation (very low certainty).
1 finding from 1 review
Cancer‐related mortality at maximal · people with hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to progression of the tumour · people with hepatocellular carcinoma
1 finding from 1 review